Adapting during a Global Pandemic: Capturing Remdesivir in the National Healthcare Safety Network (NHSN) Antimicrobial Use Option

Heather Dubendris, MSPH^{1,2}; Amy Webb, MPH, CHES^{1,2}; Melinda Neuhauser, PharmD, MPH¹; Arjun Srinivasan, MD¹; Erin O'Leary, MPH^{1,2}; Dan Pollock, MD¹ 1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 2. Lantana Consulting Group, East Thetford, VT

Background

The Centers for Disease Control and Prevention's (CDC's) National Healthcare Safety Network (NHSN) launched the Antimicrobial Use (AU) Option in 2011.

NHSN AU Option enables AU reporting and analysis in support of benchmarking and stewardship activities.

Typically, NHSN makes decisions annually about which antimicrobials to add or remove from the Option. However, more timely decisions can be made when AU data are needed on new or high-priority antimicrobials.

Methods

NHSN closely monitored new treatments for COVID-19, assessing opportunities to track use of key therapeutics.

NHSN implemented remdesivir reporting to the AU Option during an application update on 7/2/20.

The update required facilities to report remdesivir in AU files beginning with July 2020 data submissions and enabled optional submission of remdesivir for summary months January – June 2020.

NHSN tracked the number of facilities reporting use and their use at the facility and patient care location levels.

NHSN reviewed submissions for data quality concerns and conducted outreach as appropriate.

Results

5/1/20: FDA issues Emergency Use Authorization (EUA) for treatment of hospitalized COVID-19 patients with remdesivir		7/2/20: NHSN asks facilities to report remdesivir beginning with July 2020 submissions		10/1/20: Hospitals can purchase remdesivir directly from distributor		hase vir directly		
Apr.	May	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.	Dec.
	5/29/20: NHSN moves forward with adding remdesivir to the AU Option			expands	8/28/20: FDA expands EUA for remdesivir		10/22/20: FDA approves remdesivir for hospitalized COVID-19 patients	


48% (n=794) facilities optionally reported remdesivir use for June 2020. This represents 48% of all facilities submitting data for June 2020.						
1561 facilities reported >0 remdesivir use at least once, at the facility-wide inpatient (FacWideIn) level during July 2020 – May 2021. This represents 86% of all facilities submitting FacWideIn data at least once during this time period.						
21 per 1,000 days present At the FacWideIn level, the pooled mean rate of remdesivir use was 21 antimicrobial days per 1,000 days present from July 2020 through May 2021.	Du wit rer inc to and ver					

122.7 per 1,000 days present

uring June 2020 – May 2021, rates of remdesivir use ere highest in Respiratory Critical Care units (pooled ean 122.7 per 1,000 days present) followed by ulmonary wards (pooled mean 119.8 per 1,000 days resent).

uring analysis, NHSN identified 🗲 facilities ith data quality concerns related to report of mdesivir use. Subsequent outreach resulted in creased understanding of reporting practices, updates reporting plans to facilitate accurate data capture, nd increased communication between facilities and ndors.

Pooled mean rate of remdesivir in select **locations June 2020 through March 2021**



Conclusions

per

The rapid mid-year addition of remdesivir and prompt uptake in reporting by hospitals participating in NHSN's AU surveillance highlight the AU Option's flexibility, timeliness, and acceptability as a surveillance system. NHSN continues to monitor remdesivir use, explore opportunities for additional analysis and review these data for potential data quality concerns.

Contact Info

Heather Dubendris, MSPH Public Health Analyst Lantana Consulting Group Contractor for NHSN, DHQP, NCEZID, CDC Email: NHSN@cdc.gov

